Sweden's Senzime Q3 sales rise on strong sensor demand

Overview

• Sweden medical device maker's Q3 net sales rose 14% yr/yr on strong sensor demand

• Gross margin improved to 74% from 61% as recurring sensor sales grew

• EBITDA loss narrowed to SEK 8 mln from SEK 19 mln as costs declined

Outlook

• Company maintains target of achieving positive cash flow in Q4 2026

• Senzime says growing recurring revenues expected to strengthen business predictability

• Company sees long-term market opportunity with estimated 80,000 EMG-based monitors in use over next decade

Result Drivers

• RECURRING SENSOR SALES - Co said recurring sales of disposable sensors grew 43% and accounted for 83% of total Q3 sales, driving revenue growth

• REGIONAL SALES GROWTH - Co reported net sales growth across all regions, with increases of 9% in the US, 20% in Europe, and 33% in the rest of the world

• COST REDUCTIONS - Co said continued cost reductions contributed to improved cash flow and narrowed EBITDA loss

Company press release:

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• Wall Street's median 12-month price target for Senzime AB (publ) is SEK8.69, about 209.8% above its October 28 closing price of SEK2.81

Reuters Recommended Reads

• Oct 28 - Bausch + Lomb beats Q3 adjusted EPS estimates; raises FY outlook

• Oct 28 - Glaukos Q3 revenue jumps 58% on iDose TR, Epioxa launches, Corneal Health growth

• Oct 26 - France's MEMSCAP Q3 revenue rises on medical and aerospace strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)